Appili Therapeutics USA, Inc.
Appili Therapeutics is dedicated to advancing the global fight against infectious diseases through innovative drug development programs. The company focuses on creating solutions for unmet patient needs across a broad spectrum of infectious diseases, including antibiotic-resistant infections and biothreats. With a pipeline that includes anti-infective programs such as ATI-1501, a taste-masked treatment for anaerobic infections, and ATI-1503, a broad-spectrum antibiotic targeting Gram-negative bacteria, Appili aims to provide effective therapies for serious health threats. The company also engages in licensing and collaboration efforts to expand its portfolio and accelerate the development and commercialization of its therapeutics.
Industries
Nr. of Employees
small (1-50)
Appili Therapeutics USA, Inc.
Halifax, Nova Scotia, Canada, North America
Products
Taste-masked oral metronidazole suspension (lead clinical candidate)
A taste-masked oral liquid suspension reformulation of metronidazole designed to improve palatability and adherence in patients (children, elderly) with difficulty swallowing; progressed through Phase 1 relative bioavailability study and intended for regulatory submission.
Negamycin-analogue antibiotic discovery program (Gram-negative focused)
A drug discovery and preclinical optimization program to generate synthetic negamycin analogue candidates with broad-spectrum activity against drug-resistant Gram-negative pathogens, employing structure-guided optimization and potency enhancement.
Live-attenuated tularemia vaccine (in-licensed preclinical candidate)
An in-licensed live-attenuated vaccine candidate derived from genetically attenuated Francisella tularensis intended to elicit protective immunity against tularemia for civilian and military biodefense applications.
Taste-masked oral metronidazole suspension (lead clinical candidate)
A taste-masked oral liquid suspension reformulation of metronidazole designed to improve palatability and adherence in patients (children, elderly) with difficulty swallowing; progressed through Phase 1 relative bioavailability study and intended for regulatory submission.
Negamycin-analogue antibiotic discovery program (Gram-negative focused)
A drug discovery and preclinical optimization program to generate synthetic negamycin analogue candidates with broad-spectrum activity against drug-resistant Gram-negative pathogens, employing structure-guided optimization and potency enhancement.
Live-attenuated tularemia vaccine (in-licensed preclinical candidate)
An in-licensed live-attenuated vaccine candidate derived from genetically attenuated Francisella tularensis intended to elicit protective immunity against tularemia for civilian and military biodefense applications.
Services
Licensing and partnering for anti-infective programs
In-licensing of external therapeutic and vaccine assets and establishing partnerships with research organizations, governments and industry to advance development and commercialization.
Clinical development and regulatory advancement
Advancement of investigational anti-infective products through IND/CTA filings, conduct of clinical bioavailability studies, and preparation for regulatory submissions and commercialization.
Licensing and partnering for anti-infective programs
In-licensing of external therapeutic and vaccine assets and establishing partnerships with research organizations, governments and industry to advance development and commercialization.
Clinical development and regulatory advancement
Advancement of investigational anti-infective products through IND/CTA filings, conduct of clinical bioavailability studies, and preparation for regulatory submissions and commercialization.
Expertise Areas
- Anti-infective drug development
- Formulation development for oral suspensions and taste-masking
- Clinical trial management and bioavailability studies
- Regulatory strategy and submissions (IND/CTA, 505(b)(2), orphan drug)
Key Technologies
- Taste-masked oral suspension formulation
- Pharmacokinetics and bioavailability studies
- Palatability assessment using hedonic scale
- X-ray crystallography for structure-guided design